Factor V Leiden in Women: A Thrombotic Risk Factor or an Evolutionary Advantage?

ABSTRACT

Factor V Leiden is a common gain-of-function gene mutation resulting in a genetic predisposition to thromboembolic complications. Growing evidence in the literature indicates an interaction between factor V Leiden thrombophilia and acquired prothrombotic conditions such as contraceptive use or hormone replacement therapy, resulting in an increased risk of venous thromboembolism (VTE). Similarly, when combined with the prothrombotic influence of pregnancy, women who are carriers of factor V Leiden are faced with an increased risk of adverse pregnancy outcomes, including VTE, pre-eclampsia, fetal loss, placental abruption, and fetal growth restriction. The results of the most important meta-analyses on the relationship between inherited (factor V Leiden) and acquired thrombophilia in women are analyzed in this review, along with the possible evolutionary role of this mutation.

KEYWORDS

Factor V Leiden - women - thrombophilia - pregnancy - thrombosis.

REFERENCES

• 1 Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders.  Blood. 2008;  112 (1) 19-27
• 2 Nicolaes G AF, Dahlbäck B. Factor V and thrombotic disease: description of a janus-faced protein.  Arterioscler Thromb Vasc Biol. 2002;  22 (4) 530-538
• 3 Franchini M, Veneri D, Salvagno G L, Manzato F, Lippi G. Inherited thrombophilia.  Crit Rev Clin Lab Sci. 2006;  43 (3) 249-290
• 4 Segers K, Dahlbäck B, Nicolaes G AF. Coagulation factor V and thrombophilia: background and mechanisms.  Thromb Haemost. 2007;  98 (3) 530-542
• 5 Bertina R M, Koeleman B P, Koster T et al.. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature. 1994;  369 (6475) 64-67
• 6 Voorberg J, Roelse J, Koopman R et al.. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V.  Lancet. 1994;  343 (8912) 1535-1536
• 7 Ridker P M, Miletich J P, Hennekens C H, Buring J E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.  JAMA. 1997;  277 (16) 1305-1307
• 8 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden.  Lancet. 1995;  346 (8983) 1133-1134
• 9 Rees D C. The population genetics of factor V Leiden (Arg506Gln).  Br J Haematol. 1996;  95 (4) 579-586
• 10 Zivelin A, Griffin J H, Xu X et al.. A single genetic origin for a common Caucasian risk factor for venous thrombosis.  Blood. 1997;  89 (2) 397-402
• 11 Lindqvist P G, Dahlbäck B. Carriership of Factor V Leiden and evolutionary selection advantage.  Curr Med Chem. 2008;  15 (15) 1541-1544
• 12 Franchini M, Mannucci P M. The hemostatic balance revisited through the lessons of mankind evolution.  Intern Emerg Med. 2008;  3 (1) 3-8
• 13 Franchini M, Mannucci P M. Multiple gene interaction and modulation of hemostatic balance.  Clin Chem Lab Med. 2009;  47 (12) 1455-1460
• 14 Pabinger I. Thrombophilia and its impact on pregnancy.  Thromb Res. 2009;  123 (Suppl 3) S16-S21
• 15 Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes.  J Thromb Haemost. 2005;  3 (8) 1603-1610
• 16 Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.  Eur J Obstet Gynecol Reprod Biol. 2002;  101 (1) 6-14
• 17 Morrison E R, Miedzybrodzka Z H, Campbell D M et al.. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review.  Thromb Haemost. 2002;  87 (5) 779-785
• 18 Rey E, Kahn S R, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis.  Lancet. 2003;  361 (9361) 901-908
• 19 Kosmas I P, Tatsioni A, Ioannidis J P. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis.  J Hypertens. 2003;  21 (7) 1221-1228
• 20 Kovalevsky G, Gracia C R, Berlin J A, Sammel M D, Barnhart K T. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis.  Arch Intern Med. 2004;  164 (5) 558-563
• 21 Dudding T E, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis.  Thromb Haemost. 2004;  91 (4) 700-711
• 22 Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis.  Obstet Gynecol. 2005;  105 (1) 182-192
• 23 Wu O, Robertson L, Langhorne P et al.. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.  Thromb Haemost. 2005;  94 (1) 17-25
• 24 Robertson L, Wu O, Langhorne P Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study et al. Thrombophilia in pregnancy: a systematic review.  Br J Haematol. 2006;  132 (2) 171-196
• 25 Biron-Andreani C, Schved J F, Daures J P. Factor V Leiden mutation and pregnancy-related venous thromboembolism: what is the exact risk? Results from a meta-analysis.  Thromb Haemost. 2006;  96 (1) 14-18
• 26 Dudding T, Heron J, Thakkinstian A et al.. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis.  J Thromb Haemost. 2008;  6 (11) 1869-1875
• 27 Kist W J, Janssen N G, Kalk J J, Hague W M, Dekker G A, de Vries J I. Thrombophilias and adverse pregnancy outcome—a confounded problem!.  Thromb Haemost. 2008;  99 (1) 77-85
• 28 Wu O, Robertson L, Twaddle S et al.. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.  Health Technol Assess. 2006;  10 (11) 1-110
• 29 Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci P M. Hyperhomocysteinemia in cerebral vein thrombosis.  Blood. 2003;  102 (4) 1363-1366
• 30 Gerhardt A, Scharf R E, Beckmann M W et al.. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med. 2000;  342 (6) 374-380
• 31 Bloomenthal D, von Dadelszen P, Liston R, Magee L, Tsang P. The effect of factor V Leiden carriage on maternal and fetal health.  CMAJ. 2002;  167 (1) 48-54
• 32 Bates S M, Greer I A, Pabinger I, Sofaer S, Hirsh J. American College of Chest Physicians . Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 (6, Suppl) 844S-886S
• 33 Kutteh W H, Triplett D A. Thrombophilias and recurrent pregnancy loss.  Semin Reprod Med. 2006;  24 (1) 54-66
• 34 Lindqvist P G, Svensson P J, Dahlbäck B, Marsál K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss—a possible evolutionary selection mechanism.  Thromb Haemost. 1998;  79 (1) 69-73
• 35 Lindqvist P G, Zöller B, Dahlbäck B. Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden—an evolutionary advantage?.  Thromb Haemost. 2001;  86 (4) 1122-1123
• 36 Isma N, Breslin T, Lindblad B, Svensson P J. The Factor V Leiden mutation is associated with a higher blood haemoglobin concentration in women below 50 of the Malmö Thrombophilia Study (MATS).  J Thromb Thrombolysis. 2009;  28 (3) 255-258
• 37 Clark P, Walker I D, Govan L, Wu O, Greer I A. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes.  Br J Haematol. 2008;  140 (2) 236-240
• 38 Göpel W, Ludwig M, Junge A K, Kohlmann T, Diedrich K, Möller J. Selection pressure for the factor-V-Leiden mutation and embryo implantation.  Lancet. 2001;  358 (9289) 1238-1239